About ABclonal Biotechnology
ABclonal Biotechnology is a Healthcare company based in Woburn (United States) founded in 2006. Developer of protein and peptide reagents and kits for cell and molecular biology research. ABclonal Biotechnology has raised $281.25 million across 2 funding rounds from investors including Luxin Venture Capital Group, Sigma Square Capital and Sequoia Capital. Its website abclonal.com draws about 50 thousand monthly visits. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Diversified. Its competitors include Meridian Bioscience, Teknova and Cayman Chem.
Company details
ABclonal Biotechnology was founded in 2006 and is based in Woburn, United States, within the biotechnology sector. Protein reagents and kits for cell and molecular biology research are produced, including monoclonal and polyclonal antibodies, recombinant proteins, ELISA kits, and gene clones. Services such as peptide synthesis, custom antibody development, and protein expression in bacterial, insect, yeast, or mammalian systems are offered to support research operations.
- Headquarters Woburn, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website abclonal.com
- Social LinkedIn X Facebook
- Total Equity Funding$281.25M (USD)
in 2 rounds
- Latest Funding Round$188.35M (USD), Series D
Dec 2021
- InvestorsLuxin Venture Capital Group
& 8 more
Funding Insights of ABclonal Biotechnology
ABclonal Biotechnology has successfully raised a total of $281.25M across 2 strategic funding rounds. The most recent funding activity was a Series D round of $188.35 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $281.25M
- Total Rounds 2
- Last Round Series D — $188.35M
- First Round $92.9M
(Jun 2020)
- Investors Count 9
All 2 funding rounds of ABclonal Biotechnology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2021 | $188.35M | Series D | – | Sequoia Capital China | |
| Jun 2020 | $92.9M | Series C | – | Sequoia Capital, LYFE Capital |
9 investors in total: 9 institutional.
Investors in ABclonal Biotechnology
ABclonal Biotechnology has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Luxin Venture Capital Group, Sigma Square Capital and Sequoia Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Mid-market companies are targeted for investment by Loayal Valley Capital. | loyalvalleycapital.com | Shanghai, China | ||
Sequoia Capital is engaged in venture capital investments. | 1972 | sequoiacap.com | ||
LYFE Capital is recognized as a premier healthcare investment platform. | lyfecapital.com | Menlo Park, USA | ||
| chinacdc.com | ||||
Venture capital firm focused on early-stage investments | sequoiacap.cn | Beijing, China | ||
| cmbi.com.hk | ||||
Manufacturer of abrasives and venture capital firm | 1988 | 600783.cn | Jinan, China | |
| taikangasset.cn | ||||
Manages diversified investment portfolios across various asset classes. | sigmasquarecapital.com | Thane, India |
Investor details for ABclonal Biotechnology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ABclonal Biotechnology
9 people are tracked at ABclonal Biotechnology (6 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Alex Zong | Vice President, Global Marketing & Oversea Market Development | Leadership |
知才 吴 | CEO | Leadership |
YANG LOU | Senior Vice President (S.V.P) | Leadership |
Dapeng Sun | Executive Vice President | Leadership |
Hai Wu | CTO & Head, Immunology Business Unit | Leadership |
Chaoxiong | Vp, Business Development | Leadership |
Panyue (Penny) Hao | PR & Branding Strategist | Team |
Terry Pan | Product Manager In Europe | Team |
Donal Zhang | Business Development | Team |
Complete people profiles for ABclonal Biotechnology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ABclonal Biotechnology
3 dated milestones of ABclonal Biotechnology across 15 years, from founding to its latest funding, stage changes and deals.
- Founded ABclonal Biotechnology is founded.
- Funding First funding round of $92.9M.
- Funding Latest funding round, Series D, of $188.3M.
Competitors of ABclonal Biotechnology
ABclonal Biotechnology has 3 listed competitors in our database. They include Meridian Bioscience, Teknova and Cayman Chem.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| meridianbioscience.com | 1976 | Ohio, United States | Molecular diagnostic device and kits | |||
| teknova.com | 1996 | Hollister, United States | 290 | Molecular biology reagents and kits are supplied for research applications. | ||
| caymanchem.com | 1980 | Ann Arbor, United States | 309 | Bioreagents and assay kits are developed, with preclinical services provided. |
Detailed competitors of ABclonal Biotechnology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ABclonal Biotechnology
The website of ABclonal Biotechnology (abclonal.com) receives about 50.4K visits a month.
- Monthly visits50.4K
▲ 2.8% vs previous month
Websites whose visitors overlap most with ABclonal Biotechnology. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| alpco.com | 100% | 22.6K | #1,367,181 | View details | |
| vectorlabs.com | 100% | 65.9K | #500,436 | View details | |
| genelink.com | 99% | 10.8K | #2,265,843 | View details | |
| bpsbioscience.com | 99% | #779,448 | View details | ||
| abcam.com | 95% | 602.8K | #91,958 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for ABclonal Biotechnology
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as ABclonal Biotechnology (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Abclonal Biotechnology
Complete news archive for ABclonal Biotechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ABclonal Biotechnology
ABclonal Biotechnology was founded in 2006 and raised its 1st funding round 14 years after it was founded.
ABclonal Biotechnology is headquartered in Woburn, United States. It is registered at Woburn, Massachusetts, United States.
ABclonal Biotechnology is a funded company, having raised a total of $281.25M across 2 funding rounds to date. The company's 1st funding round was a Series C of $92.9M, raised on Jun 2020.
ABclonal Biotechnology was founded in 2006 and is based in Woburn, United States, within the biotechnology sector. Protein reagents and kits for cell and molecular biology research are produced, including monoclonal and polyclonal antibodies, recombinant proteins, ELISA kits, and gene clones. Services such as peptide synthesis, custom antibody development, and protein expression in bacterial, insect, yeast, or mammalian systems are offered to support research operations.
ABclonal Biotechnology's top competitors include Meridian Bioscience, Cayman Chem and Teknova.
ABclonal Biotechnology has 9 investors. Key investors include Luxin Venture Capital Group, Sigma Square Capital, Sequoia Capital, CMB International Capital, and Taikang Asset Management.